01922nas a2200373   4500000000100000008004100001260000900042653002500051653003800076653001100114653001100125653004600136653002200182653001200204653002500216653000900241653001600250653001400266100001300280700001700293700001100310700001400321700001500335700001300350700001300363700001600376700001600392700001600408245013400424300001100558490001500569520095000584022001401534       2008                            d  c200810aCase-Control Studies10aEnzyme-Linked Immunosorbent Assay10aFemale10aHumans10aInterleukin 1 Receptor Antagonist Protein10aInterleukin-1beta10aleprosy10aLongitudinal studies10aMale10aMiddle Aged10aROC Curve1 aCosta RD1 aMendonça VA1 aLyon S1 aPenido RA1 aCosta AMDD1 aCosta MD1 aNishi MP1 aTeixeira MM1 aTeixeira AL1 aAntunes CMF00aEvaluation of the expression of interleukin 1 beta (IL-1beta) and interleukin 1 receptor antagonist (IL-1Ra) in leprosy patients.  a99-1030 v41 Suppl 23 a<p>Leprosy is an infectious and contagious spectral disease accompanied by a series of immunological events triggered by the host's response to the etiologic agent, Mycobacterium leprae. Evidence suggests that the induction and maintenance of the immune/inflammatory response in leprosy are linked to multiple cell interactions and soluble factors, mainly through the action of cytokines. The ELISA test was used to measure the levels of IL-1beta and IL-1Ra in 37 new leprosy patients followed-up during treatment and 30 healthy controls. Peripheral blood was collected four times during the treatment of leprosy patients (MDT pretreatment, 2nd dose, 6th dose and post-MDT), and only once from the controls. The comparison of molecular levels in pre-MDT patients and controls showed a statistically significant difference for IL-1beta. The results suggest the participation of this cytokine in the genesis of the immune/inflammatory process.</p>  a1678-9849